In this article, we will discuss the 10 Unstoppable Stocks to Buy in 2025.
As per the recent earnings update by FactSet dated 24th January 2025, the Q4 2024 earnings season for the S&P 500 has seen a strong start. Notably, the percentage of S&P 500 companies publishing positive earnings surprises and the magnitude of earnings surprises are more than 10-year averages. The analysts anticipate YoY earnings growth rates of 11.3% and 11.6% for Q1 2025 and Q2 2025, respectively. For CY 2025, they project a YoY earnings growth of 14.8%.
Outlook for US Equities For 2025
UBS expects the S&P 500 to reach 6,600 by 2025. Despite the potential for tariff imposition, which can result in volatility over the short term, UBS expects that healthy US economic growth and structural tailwinds from AI might lend some support. The combination- resilient growth and lower Fed rates- has earlier been a powerful force for US stocks. History has suggested that when the Fed cut rates and the country did not enter recession, the broader US equities saw an increase of 18% on average in the 12 months after the first cut.
UBS also believes that the earnings season showcases strong AI capital spending intentions, which supports the positive outlook on technology stocks. Furthermore, the earnings growth continues to broaden into non-tech companies. The US deregulation and tax cuts might support this trend.
READ ALSO: 7 Best Stocks to Buy For Long-Term and 8 Cheap Jim Cramer Stocks to Invest In.
Growth Drivers for the US Equities
UBS expects that the US economic backdrop remains supportive, the broader market is less at risk from tariffs compared to other international markets, and structural trends around AI and power & resources boost the outlook. It believes technology, utilities, financials, and healthcare sectors are attractive in the US. The AI infrastructure spending is strong, and the firm expects that key semiconductor components required for AI will remain supply-constrained in 2025, supporting pricing. Furthermore, the tech sector is expected to benefit from an improvement in PC and smartphone end markets.
With respect to utilities, UBS expects that significant growth in AI data centers will fuel power demand, resulting in higher power prices. While the broader financials sector is expected to be aided by Fed rate cuts, the healthcare sector might see recovery in the next few months. This recovery is expected to be driven by higher healthcare spending and advancements in digitalization that can fuel efficiency and reduce costs.
With this in mind, we will now have a look at the 10 Unstoppable Stocks to Buy in 2025
Our Methodology
To list the 10 Unstoppable Stocks to Buy in 2025, we used a screener to filter out the companies having at least $2 billion of market capitalization. Next, we chose stocks that have gained more than 30% over the past 6 months and in which analysts expect an upside of at least 30%. Finally, the stocks were arranged in ascending order of their average upside potential, as of 27 January. We also mentioned the hedge fund sentiment around each stock, as of Q3 2024.
At Insider Monkey we are obsessed with the stocks that hedge funds pile into. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
10 Unstoppable Stocks to Buy in 2025
10) Rumble Inc. (NASDAQ:RUM)
Market Cap as of 27th January: $4.83 billion
Return Over 6 Months: ~97.8%
Average Upside Potential: 31%
Number of Hedge Fund Holders: 6
Rumble Inc. (NASDAQ:RUM) operates video-sharing platforms, offering a space for content creators to upload, share, and monetize their videos. Maxim Group analyst initiated coverage on the company’s shares, setting a price target of $20 with a Buy rating. As per the analyst Tom Forte, Rumble Inc. (NASDAQ:RUM) has established itself as a strong contender in the video space, thanks to solid user growth. Notably, the company saw average global monthly active users of 67 million in Q3 2024 as compared to 53 million in Q2 2024. Therefore, this marks the 11th consecutive quarter above 40 million average global MAUs on the platform.
Analyst Tom Forte believes that Rumble Inc. (NASDAQ:RUM)’s cloud-computing capabilities might act as an enterprise alternative to big tech. Furthermore, he added that the market has been underestimating the company’s potential to monetize its audience and, over time, establish a sound cloud computing business. Notably, the company is expected to achieve a positive FCF by 2026. There is enough capital to finance operations and growth going forward, says Forte.
Rumble Inc. (NASDAQ:RUM)’s honest commitment to offering a transparent, unbiased space is the main reason for the growth of the platform. The company has also entered into a definitive agreement for a strategic investment of $775 million from Tether. It would be using $250 million of the proceeds to aid its growth initiatives.
9) BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Market Cap as of 27th January: $6.85 billion
Return Over 6 Months: ~38.2%
Average Upside Potential: 32.1%
Number of Hedge Fund Holders: 46
BridgeBio Pharma, Inc. (NASDAQ:BBIO) is a commercial-stage biopharmaceutical company, that discovers, creates, tests, and delivers transformative medicines to help patients suffering from genetic diseases and cancers. BofA upped the company’s price target to $45 from $42, maintaining a “Buy” rating after BridgeBio Pharma, Inc. (NASDAQ:BBIO) announced that the FDA has approved its stabilizer acoramidis as Attruby for ATTR-CM. The growth in its stock price was aided by the strong commercial uptake. The company noted the associated initial commercial momentum, with 430 prescriptions written by 248 unique physicians.
On November 22, 2024, the U.S. Food and Drug Administration (FDA) approved Attruby (acoramidis). To provide a brief context, Attruby treats cardiomyopathy, in which abnormal protein builds up on the heart muscle, leading to problems. Mizuho Securities analyst Salim Syed maintained a bullish stance on BridgeBio Pharma, Inc. (NASDAQ:BBIO)’s stock, providing a “Buy” rating. As per the analyst, the current market consensus for Attruby’s 2025 sales remains underestimated. The sales are expected to increase as and when the drug captures new and switch patients.
Notably, BridgeBio Pharma, Inc. (NASDAQ:BBIO) has also announced that the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization in the European Union (EU) for acoramidis for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
8) Summit Therapeutics Inc. (NASDAQ:SMMT)
Market Cap as of 27th January: $17.3 billion
Return Over Past 6 Months: ~118.1%
Average Upside Potential: ~33.9%
Number of Hedge Fund Holders: 21
Summit Therapeutics Inc. (NASDAQ:SMMT) is a biopharmaceutical company, focusing on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies. Analyst Mitchell Kapoor of H.C. Wainwright reiterated a “Buy” rating on the company’s shares, retaining the price objective of $44.00. The analyst’s rating is backed by several factors revolving around the strong outlook of Summit Therapeutics Inc. (NASDAQ:SMMT)’s key drug candidate, ivonescimab.
The analyst noted that the drug’s efficacy and safety profile are expected to place it favorably as compared to existing treatments in non-small cell lung cancer (NSCLC), primarily in patients who have not responded to EGFR tyrosine kinase inhibitors. Furthermore, Summit Therapeutics Inc. (NASDAQ:SMMT)’s management also emphasized the comprehensive advantages of ivonescimab, highlighting that even if the overall survival hazard ratio doesn’t outpace competitors significantly, the lower toxicity can offer a meaningful benefit. Also, the recent financing in September 2024 provided Summit Therapeutics Inc. (NASDAQ:SMMT) $235 million, strengthening its cash balance to extend the cash runway.
The company’s cash balance at quarter-end aggregated to $487 million, which provides Summit Therapeutics Inc. (NASDAQ:SMMT) enough cash to continue to invest in the ivonescimab trials planned to be expanded and initiated in 2025. Bronte Capital, an investment management company, released its Q3 2024 investor letter. Here is what the fund said:
“The short book hurt us in many ways. Several deeply junky stocks went up – and one – Summit Therapeutics Inc. (NASDAQ:SMMT) – in which we may have made a mistake – stood out above all. Even excluding Summit, our short book would have faced challenges in September, but this position exacerbated the difficulties.
A little background is necessary. Summit is (or was) a small drug company that we scored as having some suspect associations and hence a short candidate. Our database of bad people in financial markets is very broad. Summit was not such a stock. Our short signals were triggered light amber, not bright red. This meant the company required a bit more analysis…” (Click here to read the full text)